Autologous Transplant for Multiple Myeloma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

363

Participants

Timeline

Start Date

April 20, 2004

Primary Completion Date

August 1, 2020

Study Completion Date

August 1, 2020

Conditions
Multiple Myeloma
Interventions
PROCEDURE

Stem Cell Transplant

As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.

DRUG

Cyclophosphamide + Mesna

Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.

DRUG

Melphalan

Administered intravenously 200 mg/m\^2

BIOLOGICAL

Granulocyte-colony stimulating factor

Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00177047 - Autologous Transplant for Multiple Myeloma | Biotech Hunter | Biotech Hunter